How much cash does Apogee Therapeutics, Inc. generate?

Apogee Therapeutics, Inc. (APGE) generated -$234.5M in operating cash flow over the trailing twelve months.

What is Apogee Therapeutics, Inc.'s free cash flow?

After $5.1M of capital expenditures, Apogee Therapeutics, Inc.'s free cash flow was -$232.6M over the trailing twelve months, down 35.0% year over year.

Where does Apogee Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Apogee Therapeutics, Inc. APGE Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$274.62M-7.3%	-$255.84M-0.9%	-$253.67M-6.7%	-$237.67M-15.7%	-$205.39M-12.8%
Depreciation and amortization	$1.61M+14.2%	$1.41M+30.5%	$1.08M+48.2%	$731K+99.2%	$367K+94.2%
Stock-based compensation	$52.31M+13.0%	$46.28M+10.3%	$41.96M+16.8%	$35.92M+18.7%	$30.27M+29.7%
Change in accounts payable	-$1.21M-905%	$150K+108%	-$1.84M-1,319%	$151K+108%	-$1.86M-73.2%
Change in accrued liabilities	$957K+189%	-$1.07M—	——	——	——
Change in other assets	$1.54M-81.9%	$8.54M—	——	——	——
Change in operating lease liabilities	-$3.77M+5.3%	-$3.98M-21.2%	-$3.29M-30.2%	-$2.52M-40.5%	-$1.8M-71.9%
Net cash from operating activities	-$234.54M-3.1%	-$227.45M+2.2%	-$232.48M-5.3%	-$220.74M-17.4%	-$188.02M-9.8%
Capital expenditures	——	$5.15M+1.2%	$5.09M-12.9%	$5.84M+14.0%	$5.12M+344%
Net cash from investing activities	-$227.91M-26.9%	-$179.57M—	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Net cash from financing activities	$807.04M+104%	$396.49M+502%	$65.9M+41.6%	$46.54M+2.6%	$45.36M-90.8%
Net increase (decrease) in cash	——	——	——	——	——
Depreciation	$1.61M+14.2%	$1.41M+30.5%	$1.08M+48.2%	$731K+99.2%	$367K+94.2%
Operating lease liabilities	-$3.77M+5.3%	-$3.98M-21.2%	-$3.29M-30.2%	-$2.52M-40.5%	-$1.8M-71.9%
Prepaid expenses and other current assets	——	——	$4.34M-13.9%	$5.05M+35.6%	$3.72M-38.8%
Investment Income, Amortization of Discount	$6.67M-11.1%	$7.5M-14.2%	$8.75M-17.7%	$10.63M-10.7%	$11.91M-2.7%
Non Cash Lease Expense	$3.8M+3.3%	$3.68M+5.7%	$3.48M+18.9%	$2.93M+28.1%	$2.29M+34.9%
Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net Of Issuance Costs	——	$324.05M-8.9%	$355.53M-8.1%	$387M-7.5%	$418.48M-7.0%
Proceeds From Issuance Of Common Stock Under At The Market Equity Offering Program Net Of Issuance Costs	——	$65.58M+9.2%	$60.07M+10.1%	$54.56M+11.2%	$49.04M+12.7%
Proceeds From Issuance Of Common Stock Under The At The Market Net Of Issuance Costs	——	——	——	——	——
Accrued payables for capital expenditures	——	——	——	——	——
Increase Decrease In Operating Lease Liability	-$3.77M+5.3%	-$3.98M-21.2%	-$3.29M-30.2%	-$2.52M-40.5%	-$1.8M-71.9%
Leased assets obtained in exchange for operating lease liabilities	——	——	——	——	$11.84M+9.2%
Issuance of common stock for the acquisition of Ansys	——	——	——	——	——
Deferred Financing Issuance Costs In Accounts Payable And Accrued Expenses	——	——	——	——	——
Unpaid Financing Cost In Accrued Liability	——	——	——	——	——
Free cash flow	——	-$232.6M+2.1%	-$237.56M-4.8%	-$226.58M-17.3%	-$193.13M-12.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Apogee Therapeutics, Inc. generate?: Apogee Therapeutics, Inc. (APGE) generated -$234.5M in operating cash flow over the trailing twelve months.
What is Apogee Therapeutics, Inc.'s free cash flow?: After $5.1M of capital expenditures, Apogee Therapeutics, Inc.'s free cash flow was -$232.6M over the trailing twelve months, down 35.0% year over year.
Where does Apogee Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.